Phase III Protocol Cleared for Grass Vaccine
Allergy Therapeutics Stock Surges as FDA Lifts Hold
By Cormac Sheridan
Monday, August 6, 2012
Shares in Allergy Therapeutics plc surged 36 percent Friday on news that the FDA had finally lifted a five-year clinical hold on the development of its Monophosphoryl Lipid A (MPL)-adjuvanted grass pollen allergy vaccine (Grass MATA MPL/ Pollinex Quattro Grass 0.5ml) and had cleared a Phase III protocol for determining the product's efficacy.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.